<DOC>
	<DOCNO>NCT01658527</DOCNO>
	<brief_summary>The objective randomized phase II open label trial determine anti-tumor activity TAK-700 ( Orteronel ) compare bicalutamide term clinical progression-free survival prostate cancer patient fail 1st line treatment LHRH ( luteinizing hormone-releasing hormone ) agonists surgical castration .</brief_summary>
	<brief_title>TAK-700 Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis prostate adenocarcinoma Metastatic disease bone lesion document image . Abnormal 99mTcbone scan imaging must confirm Computed Tomography ( CT ) Scan Magnetic resonance Imaging ( MRI ) Progressive disease follow 1st line androgen deprivation therapy LHRH ( luteinizing hormonereleasing hormone ) Agonists surgical castration . Recommendations Prostate Cancer Working Group 2 ( PCWG2 ) WHO ( World health organization ) performance status ≤ 2 Life expectancy &gt; 12 week Adequate bone marrow function ( Absolute neutrophil count ( ANC ) 1500/μL ; platelet 100,000/μL ) Castrate serum level testosterone ( &lt; 50 ng/dL ) Adequate renal function : calculated creatinine clearance &gt; 40 mL/minute Adequate hepatic function : Bilirubin : total bilirubin 1.5 Upper limit Normal ( ULN ) Asparate aminotransferase ( AST ) and/or Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN absence liver metastases ≤ 5 x ULN liver metastasis present Patients reproductive potential use adequate birth control measure , define investigator , study treatment period least 4 month follow last study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly Before patient registration/randomization , write informed consent must give accord ICH/GCP ( International conference HarmonizationGood Clinical Practices ) , national/local regulation Exclusion criterion Cardiac function : Screening calculated ejection fraction ( Multi Gated Acquisition Scan ( MUGA ) scan , echocardiogram ) must ≥ 50 % No history myocardial infarction , unstable symptomatic ischemic heart disease , ongoing arrhythmia Grade &gt; 2 thromboembolic event ( e.g. , deep vein thrombosis , pulmonary embolism , symptomatic cerebrovascular event ) , cardiac condition ( e.g. , pericardial effusion restrictive cardiomyopathy ) within 6 month prior first dose study drug Chronic stable atrial fibrillation stable anticoagulant therapy allow Absence New York Heart Association Class III IV heart failure Absence Electrocardiogram ( ECG ) abnormality : Qwave infarction , unless identify 6 month prior screen QTc interval &gt; 470 msec No uncontrolled hypertension despite appropriate medical therapy define blood pressure &gt; 160/90 mmHg 2 separate measurement 60 minute apart Screening visit Prior radiotherapy lymph node allow Prior concomitant therapy : No intake narcotic analgesia bone pain No prior treatment nonsteroidal antiandrogens , within 6 month prior randomization No anticancer therapy treatment another investigational agent within last 4 week prior randomization No prior therapy TAK700 , ketoconazole , abiraterone , aminoglutethimide MDV3100 Patients take bisphosphonates denosumab eligible receive stable dose 4 week prior randomization . ( These treatment may continue study ) No know hypersensitivity compound related TAK700 TAK700 excipients ( refer Investigator 's brochure ) No know gastrointestinal ( GI ) disease GI procedure could interfere GI absorption tolerance TAK700 , include difficulty swallow tablet No prior history adrenal insufficiency No prior history malignancy prostate adenocarcinoma ( except basal cell squamous cell carcinoma skin ) , patient free malignancy period 3 year prior first dose study drug No known active chronic hepatitis B C , lifethreatening illness unrelated cancer , serious medical psychiatric illness could , investigator 's opinion , potentially interfere participation study No drug alcohol abuse Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>prostate cancer</keyword>
</DOC>